;

Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Home > Finance > Sanofi to acquire Dren Bio's immunology unit

Finance

Sanofi to acquire Dren Bio's immunology unit

Published by Global Banking and Finance Review

Posted on March 20, 2025

Featured image for article about Finance

(Reuters) - Sanofi on Thursday announced an agreement with biopharmaceutical company Dren Bio for the acquisition of its autoimmune disease treatment DR-0201.

The French healthcare group will acquire the Dren Bio affiliate Dren-0201 for an upfront payment of $600 million and potential future payments totalling $1.3 billion, it said in a statement.

The transaction is expected to close in the second quarter of 2025, it added.

(Reporting by Alban Kacher)

More from Finance

Explore more articles in the Finance category

Swedish greenhouse gas emissions on rise again after government relaxes fuels policy, data shows

Eurovision host says it will not drown out any boos during Israel's performance

From pulpit to turntables: Portugal's 'DJ Priest' brings his message to Latin America

Leonardo denies liability for helicopter crash that killed Leicester City owner

Explainer-French lawmakers race to agree 2026 budget before year-end

UK's FTSE 100 falls as oil, defence stocks weigh; domestic unemployment climbs

Sterling rises after UK economic data, US figures in focus

Sonnedix wins contracts for 805 MW of solar capacity in Italy

German financial watchdog finds non-compliance at local Standard Chartered unit

European economies end year resilient but sluggish

German investor morale rises more than expected in December, ZEW finds

Exclusive-Shell seeks buyers for stake in Germany's Schwedt refinery, sources say

View All Finance Posts